How can treatment response be measured in breast cancer patients?
Serum TPS, CA 15-3 and CEA levels were measured in 31 women when progressive metastatic disease was established according to UICC criteria. A method was developed to apply these serum tumor markers in order to measure the short-term effect of the treatment. Using strict criteria, whereby an increase of the markers of more than 25% indicated progressive disease and a decrease of more than 50% indicated a positive effect of the treatment, TPS (which measures tumoral activity) was shown to be a more sensitive and earlier marker for measuring treatment response than CA 15-3 and CEA (which measure tumor mass).
van Dalen
A
A
Department of Nuclear Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands.
van der Linde
D L
DL
Heering
K J
KJ
van Oudalblas
A B
AB
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009362:Neoplasm Metastasis; D010455:Peptides / Q000032:analysis; D012189:Retrospective Studies; D019396:Tissue Polypeptide Antigen
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010455:Peptides; D019396:Tissue Polypeptide Antigen